Reuters logo
2 months ago
BRIEF-ProQR receives fast track designation from FDA for QR-110
May 31, 2017 / 11:13 AM / 2 months ago

BRIEF-ProQR receives fast track designation from FDA for QR-110

1 Min Read

May 31 (Reuters) - ProQR Therapeutics NV

* ProQR receives fast track designation from the FDA for QR-110 for leber’s congenital amaurosis type 10

* ‍top-line trial results are expected in 2018

* ‍QR-110 is currently in clinical development with planned phase 1/2 open-label trial (PQ-110-001)​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below